Quantcast
Last updated on April 19, 2014 at 21:20 EDT

Latest Prize4Life Stories

2013-04-10 23:00:36

Winners Announced at Bio-IT World Expo Conference in Boston Boston, MA (PRWEB) April 10, 2013 Bio-IT World announced the winners of its ninth Best Practices Awards competition this morning in a plenary session at the 2013 Bio-IT World Conference & Expo in Boston. Grand prize winners were named in four life sciences categories highlighting best practices in genomics, cloud computing, big data in disease research, and big pharma data management from the Genomic Medicine Institute at...

2013-03-13 08:34:40

James Berry, M.D., M.P.H., 2013 Recipient WASHINGTON, March 13, 2013 /PRNewswire-USNewswire/ -- The ALS Association and the American Academy of Neurology (AAN) are pleased to announce that James Berry, M.D., M.P.H., from the Department of Neurology, Massachusetts General Hospital, Boston, Mass., is this year's recipient for the Richard Olney AAN/ALS Association Clinician Scientist Development Award, which is a part of The Association's research program TREAT ALS (Translational Research...

2013-01-12 05:00:02

Sentrana researchers presented Prize4Life ALS Prediction Challenge research that will help accelerate the discovery of treatments and a cure for ALS . Washington, DC (PRWEB) January 11, 2013 Dr. Liuxia Wang and modeler Guang “Eric” Li of Sentrana´s quantitative modeling research department presented their prize winning research at the international Research in Computational Molecular Biology (RECOMB) conference. The DREAM — Phil Bowen ALS Prediction Prize Challenge...

2012-12-22 05:01:54

Prize4Life, a nonprofit organization whose mission is to accelerate the discovery of treatments and a cure for ALS (Amyotrophic Lateral Sclerosis, also known as Lou Gehrig´s disease), is pleased to announce the appointment of Mr. Peter Frates and Ms. Jennifer Mayo to the organization´s Board of Directors. Cambridge, MA (PRWEB) December 21, 2012 Prize4Life, a nonprofit organization whose mission is to accelerate the discovery of treatments and a cure for ALS (Amyotrophic Lateral...

2012-11-30 12:25:23

WASHINGTON, Nov. 30, 2012 /PRNewswire-USNewswire/ -- The ALS Association will add ten awards totaling $2.9 million to its Translational Research Advancing Therapies for ALS (TREAT ALS(TM)) portfolio, funding two clinical management grants, three drug discovery contracts, two clinical pilot studies and three biomarker studies--all focused on finding improved treatments for people with amyotrophic lateral sclerosis (ALS), otherwise known as Lou Gehrig's disease. The ALS Association's TREAT ALS...

2012-11-06 16:26:02

WASHINGTON, Nov. 6, 2012 /PRNewswire-USNewswire/ -- According to a new study published online on October 31 in the Journal of Neurology, Neurosurgery and Psychiatry, a protein in the blood may serve as a biomarker, providing amyotrophic lateral sclerosis (ALS) researchers a way to track the progress of the disease and potentially to determine quickly whether a patient is responding to therapy. The study was supported by the EMD/ALS Biomarker Research Fund through the Keith Worthington Chapter...

2012-10-10 07:28:36

CAMBRIDGE, Mass., Oct. 10, 2012 /PRNewswire/ -- DART Therapeutics, LLC, an innovative, new-model biotechnology firm focused on developing therapies for Duchenne Muscular Dystrophy (DMD), announced today the successful completion of a study to evaluate a promising new biomarker for DMD. The biomarker, electrical impedance myography (EIM), is a non-invasive and simple-to-use technique that allows the operator to measure the health of a muscle and track its changes over time. The...

2012-08-06 06:24:27

WASHINGTON, Aug. 6, 2012 /PRNewswire-USNewswire/ -- In a new study on amyotrophic lateral sclerosis (ALS) published today in the Journal of Clinical Investigation, which was funded in part by The ALS Association, and conducted by researchers at Harvard Medical School, Tufts Medical School, Brigham and Women's Hospital and Massachusetts General Hospital, scientists have identified a biomarker in the blood that signals the earliest stages of the disease. While further studies to validate this...

2012-07-11 02:26:15

WALTHAM, Mass., July 11, 2012 /PRNewswire/-- InnoCentive, Inc., the pioneer in open innovation, crowdsourcing, and prize competitions, today announced a computational Challenge to predict the future progression of disease in Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease. The DREAM-Phil Bowen ALS Prediction Prize4Life Challenge (or ALS Prediction Prize) is being run by Prize4Life, Inc. in collaboration with The DREAM Project and carries a $25,000 prize for the...

2010-11-30 06:30:00

PALO ALTO, Calif., Nov. 30, 2010 /PRNewswire/ -- Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet medical needs, primarily for the treatment of neurodegenerative diseases, announced today top-line results from the Company's Phase 1 clinical study of NP001 for the treatment of Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease). NP001 is a small molecule regulator...